Zobrazeno 1 - 10
of 65
pro vyhledávání: '"C H, Takimoto"'
Autor:
M. K. Leabman, G. Hernandez, C. M. Ng, J. Tang, D. Pandya, K. C. Hart, K. Li, P. R. Hinton, J. So, I. Qazi, C. Y. Cheah, W. S. Kim, E. Budde, A. K. Gopal, T. Manley, C. H. Takimoto, A. M. Sinclair, S. F. Carroll, B. A. Keyt, M. F. Kotturi
Publikováno v:
HemaSphere, Vol 6, Pp 1161-1162 (2022)
Externí odkaz:
https://doaj.org/article/0b096a9e042e4b0d89131ab7c9e7b9c8
Publikováno v:
Holland-Frei Cancer Medicine
Autor:
C. H. Takimoto, Mina Nikanjam, Orren Beaty, Clinton F. Stewart, Maryam Fouladi, Edmund V. Capparelli, Timothy W. Synold
Publikováno v:
Cancer Chemotherapy and Pharmacology. 75:495-503
To characterize the determinants of variability for oxaliplatin pharmacokinetics including age, renal function, and hepatic function in children and adults.Oxaliplatin pharmacokinetic data were combined from phase I and II clinical trials: three pedi
Autor:
Anthony W. Tolcher, Urvi Aras, Patricia D. Meholick, Thomas A. Puchalski, Honghui Zhou, C. H. Takimoto, Johann S. de Bono, Thomas J. McIntosh, Hugh M. Davis, Shobha Seetharam, Gerald J. Fetterly, Shahneen Sandhu
Publikováno v:
The Journal of Clinical Pharmacology. 53:1020-1027
The chemokine ligand 2 (CCL2) promotes angiogenesis, tumor proliferation, migration, and metastasis. Carlumab is a human IgG1 monoclonal antibody with high CCL2 binding affinity. Pharmacokinetic/pharmacodynamic data from 21 cancer patients with refra
Autor:
C. H. Takimoto, Kenneth J. Pienta, Jean-Pascal Machiels, Yusri Elsayed, Mikhail Shkolnik, Susan Li, Johann S. de Bono, Fitzroy Dawkins, Simon J. Crabb, Shobha Seetharam, D. Schrijvers, Thomas A. Puchalski, Boris Alekseev
Publikováno v:
Investigational New Drugs. 31:760-768
Background CC-chemokine ligand 2 (CCL2) promotes tumor growth by angiogenesis, macrophage infiltration and tumor invasion, and distant metastasis. Carlumab (CNTO 888) is a human IgG1κ mAb with high affinity and specificity for human CCL2. Preclinica
Publikováno v:
Cancer Chemotherapy and Pharmacology. 67:985-994
The objective of this study was to develop a mechanism-based population pharmacokinetic/pharmacodynamic (PK/PD) model in describing troxacitabine-induced neutropenia in patients with cancer.A total of 727 PK/PD samples from 31 patients with cancer we
Autor:
Frederico Rojo, José Baselga, Herlinde Dumez, Eric Walk, Patrick Schöffski, Alain C. Mita, Allan T. van Oosterom, C. H. Takimoto, William Mietlowski, Josep Tabernero, Margaret Dugan, Kathryn Parker, Erika Martinelli, J. Huang, Christie Low, Clifford DiLea
Purpose: In this first-in-human study of AEE788, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), HER-2, and VEGFR-2, a comprehensive pharmacodynamic program was implemented in addition to the evaluation of safety, pharmacokine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e7bf3b6ad6ae93381430e750006ac20
http://hdl.handle.net/11591/372601
http://hdl.handle.net/11591/372601
Autor:
C H, Takimoto
Publikováno v:
Cancer treatment and research. 106
Autor:
O S, Breathnach, M S, Georgiadis, B S, Schuler, P, Pizzella, V, Llorens, V, Kasturi, S M, Steinberg, K, O'Neil, C H, Takimoto, B E, Johnson
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(7)
Our purpose was to determine the antitumor efficacy and safety profile of the combination of paclitaxel administered by 96-h continuous i.v. infusion followed by bolus cisplatin in patients with untreated advanced non-small cell lung cancer (NSCLC).
Autor:
J L, Grem, C H, Takimoto, P, Multani, E, Chu, D, Ryan, B A, Chabner, C J, Allegra, P G, Johnston
Publikováno v:
Cancer chemotherapy and biological response modifiers. 18